ENGN
enGene Therapeutics Inc.Company Information
- Company Name
- enGene Therapeutics Inc.
- CIK
- CIK0001980845
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ENGN: Nasdaq, ENGNW: Nasdaq
- Fiscal Year End
- October 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ENGN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-22
- Last sale
- 2024-04-22
- Shares purchased (TTM)
- 5,102
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 49,934,227
- Shares outstanding
- 69,734,610
- Ownership
- 71.61%
Earnings Market Reaction
- Filing date
- 2026-09-08
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Class A Redeemable Convertible Preferred Shares | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
Assets | ||||||||||||||||||
| Class B Redeemable Convertible Preferred Shares | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 41 | 30 | 37 | 50 | 33 | 58 | 62 | 173 | 258 | 265 | 86 | 82 | ||||||
| Class C Redeemable Convertible Preferred Shares | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Marketable Securities Current | 225 | 229 | 239 | 144 | 169 | 160 | 151 | 65 | - | - | - | - | ||||||
| Restricted Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 11 | 11 | 12 | 7 | 9 | 10 | 8 | 9 | 5 | 4 | 3 | 2 | ||||||
| Assets Current | 278 | 270 | 289 | 201 | 211 | 228 | 222 | 247 | 263 | 270 | 90 | 85 | ||||||
| Marketable Securities Noncurrent | 0 | 27 | 37 | 9 | 23 | 34 | 59 | 60 | - | - | - | - | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 7 | 7 | 7 | 8 | 8 | 2 | 2 | 2 | 2 | 2 | 2 | - | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 288 | 308 | 337 | 221 | 246 | 267 | 286 | 311 | 267 | 274 | 93 | 87 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 2 | 2 | 7 | 2 | 2 | 3 | 1 | 3 | 0 | 1 | 1 | ||||||
| Accrued Liabilities And Other Liabilities | 22 | 17 | 20 | 15 | 11 | 12 | 8 | 12 | 9 | 6 | 5 | 4 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Notes Payable Current | 0 | 0 | 0 | 8 | 5 | 4 | 2 | 1 | 1 | - | - | 1 | ||||||
| Liabilities Current | 27 | 21 | 25 | 32 | 20 | 18 | 13 | 15 | 13 | 6 | 7 | 5 | ||||||
| Long Term Notes Payable | 25 | 25 | 25 | 15 | 18 | 20 | 22 | 22 | 22 | 23 | 23 | 9 | ||||||
| Operating Lease Liability Noncurrent | 6 | 6 | 6 | 6 | 7 | 1 | 1 | 1 | 1 | 2 | 2 | - | ||||||
| Liabilities | 58 | 52 | 56 | 54 | 45 | 39 | 36 | 39 | 37 | 31 | 31 | 14 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 632 | 632 | 632 | 513 | 510 | 510 | 510 | 510 | 453 | 453 | 259 | 259 | ||||||
| Additional Paid In Capital Common Stock | 64 | 56 | 52 | 27 | 26 | 23 | 21 | 19 | 17 | 16 | 14 | 14 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -465 | -432 | -402 | -372 | -334 | -305 | -279 | -255 | -239 | -225 | -210 | -200 | ||||||
| Stockholders Equity | 230 | 255 | 282 | 168 | 201 | 227 | 250 | 273 | 230 | 243 | 62 | 72 | ||||||
| Liabilities And Stockholders Equity | 288 | 308 | 337 | 221 | 246 | 267 | 286 | 311 | 267 | 274 | 93 | 87 | ||||||
| Preferred Stock No Par Value | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Shares Issued | 67 | 67 | 67 | 52 | 51 | 51 | 51 | 51 | 44 | 44 | 23 | 23 | ||||||
| Shares Outstanding | 67 | 67 | 67 | 52 | 51 | 51 | 51 | 51 | 44 | 44 | 23 | 23 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialenGene Therapeutics Inc. (ENGN) — SEC Financial Statements & Analysis
enGene Therapeutics Inc. (ENGN) is a biological products, (no diagnostic substances) company, incorporated in Z4. enGene Therapeutics Inc. trades on Nasdaq as: ENGN, ENGNW. enGene Therapeutics Inc. (ENGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-07-31, filed with the SEC on 2026-09-08. Based on that filing, enGene Therapeutics Inc. carries a market cap of $124.82M, a P/E ratio of 0.96x, a P/B ratio of 0.54x, an enterprise value of $109.15M, and an EV/EBITDA multiple of 0.79x. On profitability, it posts a Return on Equity (ROE) of 60.50%, a Return on Assets (ROA) of 48.84%, and a Return on Invested Capital (ROIC) of 67.09%. Per share, it reports EPS of $1.87, diluted EPS of $1.87, free cash flow per share of $-1.49, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 37.63% year-over-year and EPS growth of 0.84% year-over-year. On the balance sheet, it maintains a current ratio of 10.21x, a quick ratio of 9.83x, working capital of $250.69M, a debt-to-equity ratio of 0.25x, a debt ratio of 0.2, an interest coverage ratio of 44.51x, free cash flow of $-104.00M (TTM), and net debt of $-15.67M. Figures sourced from SEC EDGAR.
- Market Cap
- $124.82M
- P/E TTM
- 0.96x
- EPS TTM
- $1.87
- P/B TTM
- 0.54x
- ROE TTM
- 60.50%
- ROA TTM
- 48.84%
- Debt To Equity
- 0.25x
- Free Cash Flow TTM
- $-104.00M
Data as of 2026-07-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is enGene Therapeutics Inc. in?
enGene Therapeutics Inc. (ENGN) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ENGN trade on?
enGene Therapeutics Inc. (ENGN) trades on the Nasdaq.
Where is enGene Therapeutics Inc. incorporated?
enGene Therapeutics Inc. is incorporated in Canada (Federal Level).
When was enGene Therapeutics Inc. (ENGN)'s most recent SEC filing?
enGene Therapeutics Inc. (ENGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-07-31, filed with the SEC on 2026-09-08.
What is ENGN's market cap?
enGene Therapeutics Inc. (ENGN) has a market capitalization of $124.82M as of 2026-07-31.
What is ENGN's P/E ratio?
enGene Therapeutics Inc. (ENGN)'s trailing twelve month P/E ratio is 0.96x as of 2026-07-31.
What is ENGN's EPS (earnings per share)?
enGene Therapeutics Inc. (ENGN)'s trailing twelve month EPS is $1.87 as of 2026-07-31.
What is ENGN's ROE (return on equity)?
enGene Therapeutics Inc. (ENGN)'s trailing twelve month Return on Equity (ROE) is 60.50% as of 2026-07-31.
What is ENGN's ROA (return on assets)?
enGene Therapeutics Inc. (ENGN)'s trailing twelve month Return on Assets (ROA) is 48.84% as of 2026-07-31.
What is ENGN's ROIC (return on invested capital)?
enGene Therapeutics Inc. (ENGN)'s trailing twelve month Return on Invested Capital (ROIC) is 67.09% as of 2026-07-31.
What is ENGN's EV/EBITDA?
enGene Therapeutics Inc. (ENGN)'s trailing twelve month EV/EBITDA is 0.79x as of 2026-07-31.